IN2015DN00847A - - Google Patents
Info
- Publication number
- IN2015DN00847A IN2015DN00847A IN847DEN2015A IN2015DN00847A IN 2015DN00847 A IN2015DN00847 A IN 2015DN00847A IN 847DEN2015 A IN847DEN2015 A IN 847DEN2015A IN 2015DN00847 A IN2015DN00847 A IN 2015DN00847A
- Authority
- IN
- India
- Prior art keywords
- disclosed
- lfa
- polymorph
- formulations
- purification
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261675663P | 2012-07-25 | 2012-07-25 | |
| US201261680099P | 2012-08-06 | 2012-08-06 | |
| US201261729294P | 2012-11-21 | 2012-11-21 | |
| PCT/US2013/052044 WO2014018748A1 (en) | 2012-07-25 | 2013-07-25 | Lfa-1 inhibitor and polymorph thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN00847A true IN2015DN00847A (pt) | 2015-06-12 |
Family
ID=49995472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN847DEN2015 IN2015DN00847A (pt) | 2012-07-25 | 2013-07-25 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US9085553B2 (pt) |
| EP (2) | EP2877465A4 (pt) |
| JP (3) | JP6607780B2 (pt) |
| KR (2) | KR102157608B1 (pt) |
| CN (2) | CN104797574B (pt) |
| AU (5) | AU2013295706A1 (pt) |
| BR (1) | BR112015001608B1 (pt) |
| CA (1) | CA2879982C (pt) |
| HK (2) | HK1210145A1 (pt) |
| IN (1) | IN2015DN00847A (pt) |
| MX (2) | MX2015001098A (pt) |
| RU (1) | RU2658015C2 (pt) |
| WO (1) | WO2014018748A1 (pt) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1881823T3 (en) * | 2005-05-17 | 2015-03-02 | Sarcode Bioscience Inc | COMPOSITION AND PROCEDURES FOR TREATMENT OF EYE DISORDERS |
| JP2011521896A (ja) * | 2008-04-15 | 2011-07-28 | サーコード コーポレイション | 免疫関連障害に対する局部治療に使用するための局所ｌｆａ−１アンタゴニスト |
| JP6607780B2 (ja) | 2012-07-25 | 2019-11-20 | サルコード・バイオサイエンス・インコーポレイテッド | Ｌｆａ−１阻害剤およびその多形 |
| ES2857730T3 (es) | 2014-09-25 | 2021-09-29 | Novartis Ag | Reacción de carboxilación de flujo continuo |
| CN107106325B (zh) | 2015-01-12 | 2021-05-25 | 科达莱昂治疗公司 | 微滴递送设备和方法 |
| WO2017152027A1 (en) | 2016-03-04 | 2017-09-08 | Rynerson James M | Method of treating an eye disorder by inhibiting or disrupting bacterial biofilm formation |
| WO2018019300A1 (zh) * | 2016-07-29 | 2018-02-01 | 武汉朗来科技发展有限公司 | 一种口服固体制剂及其应用 |
| CA3033507A1 (en) | 2016-08-12 | 2018-02-15 | Silk Technologies, Ltd. | Silk-derived protein for treating inflammation |
| CN108084067B (zh) * | 2016-11-22 | 2019-08-30 | 重庆圣华曦药业股份有限公司 | 一种立他司特中间体的制备方法 |
| CN106947792A (zh) * | 2017-03-07 | 2017-07-14 | 上海倍殊生物科技有限公司 | 一种间甲砜基‑l‑苯丙氨酸的制备方法 |
| WO2019004936A1 (en) | 2017-06-30 | 2019-01-03 | Scinopharm Taiwan, Ltd. | PROCESS FOR THE PREPARATION OF LIFITEGRAST AND INTERMEDIATES THEREOF |
| EP3658549B1 (en) | 2017-07-24 | 2021-05-05 | Interquim, S.A. | Process for preparing and purifying the lfa-1 antagonist lifitegrast |
| US20200369652A1 (en) * | 2017-08-03 | 2020-11-26 | Dr. Reddy's Laboratories Limited | Processes for preparation of lifitegrast and intermediates thereof |
| WO2019053607A1 (en) * | 2017-09-18 | 2019-03-21 | Glenmark Pharmaceuticals Limited | PROCESS FOR PREPARING LIFITEGRAST |
| US11246862B2 (en) | 2017-10-10 | 2022-02-15 | Mankind Pharma Ltd. | Process for the preparation of lifitegrast |
| WO2019097547A1 (en) | 2017-11-15 | 2019-05-23 | Cipla Limited | An improved process for the preparation of lifitegrast or salts thereof |
| US11001574B2 (en) | 2017-11-17 | 2021-05-11 | Medichem S.A. | Process to obtain a tetrahydroisoquinoline derivative |
| CN111601685B (zh) | 2018-01-15 | 2021-08-06 | 康格尼博提克斯股份公司 | 工业机器人手臂 |
| US10435395B1 (en) | 2018-03-30 | 2019-10-08 | Scinopharm Taiwan, Ltd. | Crystal forms of lifitegrast |
| US11345683B2 (en) * | 2018-03-31 | 2022-05-31 | Aurobindo Pharma Ltd | Process for the preparation of lifitegrast |
| IT201800006337A1 (it) * | 2018-06-14 | 2019-12-14 | Procedimento per la preparazione di lifitegrast | |
| CN109384717A (zh) * | 2018-10-29 | 2019-02-26 | 广安凯特制药有限公司 | 5,7-二氯-1,2,3,4-四氢异喹啉-6-甲酸盐酸盐水合物及其制备方法和用途 |
| CN111100118A (zh) * | 2018-10-29 | 2020-05-05 | 重庆圣华曦药业股份有限公司 | 一种立他司特杂质及其制备方法 |
| CN111285855A (zh) * | 2018-12-07 | 2020-06-16 | 苏州旺山旺水生物医药有限公司 | 一种制备化合物Lifitegrast的方法 |
| CN111471003B (zh) * | 2019-01-24 | 2022-09-23 | 上海皓元医药股份有限公司 | 一种立他司特中间体的制备方法 |
| US11679028B2 (en) | 2019-03-06 | 2023-06-20 | Novartis Ag | Multi-dose ocular fluid delivery system |
| EP3955926A4 (en) | 2019-04-18 | 2022-11-30 | Azura Ophthalmics Ltd. | COMPOUNDS AND METHODS FOR TREATING EYE DISORDERS |
| CN110256343A (zh) * | 2019-05-28 | 2019-09-20 | 苏州芝宇生物科技有限公司 | 3,5-二氯-4-溴异喹啉衍生物及其制备方法和应用 |
| CN112409256B (zh) * | 2019-08-21 | 2024-04-02 | 山东福长药业有限公司 | 5,7-二氯四氢异喹啉缩醛胺类化合物、其制备方法与应用 |
| CN111057003A (zh) * | 2019-12-06 | 2020-04-24 | 广安凯特制药有限公司 | 一种立他司特中间体5,7-二氯-1,2,3,4-四氢异喹啉的合成方法 |
| BR112022020948A2 (pt) | 2020-04-17 | 2023-04-11 | Kedallion Therapeutics Inc | Sistema de distribuição livre de conservantes hidrodinamicamente atuado |
| US11938057B2 (en) | 2020-04-17 | 2024-03-26 | Bausch + Lomb Ireland Limited | Hydrodynamically actuated preservative free dispensing system |
| CN111205275A (zh) * | 2020-04-22 | 2020-05-29 | 南京佰麦生物技术有限公司 | 立他司特晶型及其制备方法 |
| CN112321506B (zh) * | 2020-11-26 | 2021-12-24 | 江西天戌药业有限公司 | 一种5,7-二氯-1,2,3,4-四氢异喹啉的制备方法 |
| CN112500343B (zh) * | 2020-12-26 | 2023-04-07 | 山东金城柯瑞化学有限公司 | 5,7-二氯-1,2,3,4-四氢异喹啉盐酸盐的合成方法 |
| CN112300139A (zh) * | 2020-12-29 | 2021-02-02 | 南京佰麦生物技术有限公司 | 立他司特水合物晶型及其制备方法 |
| US11459351B1 (en) | 2021-04-05 | 2022-10-04 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| CN113880819A (zh) * | 2021-09-18 | 2022-01-04 | 浙江大学医学院附属第一医院 | 立他司特的制备方法及其中间体化合物 |
| CN114524767B (zh) * | 2022-03-11 | 2022-10-18 | 成都道合尔医药技术有限公司 | 立他司特中间体5,7-二氯-1,2,3,4-四氢异喹啉盐酸盐的合成方法 |
| CN115784950A (zh) * | 2022-12-08 | 2023-03-14 | 广东先强药业有限公司 | 一种立他司特中间体的制备方法 |
| CN116239532B (zh) * | 2022-12-19 | 2023-11-07 | 浙江博崤生物制药有限公司 | 一种二氯四氢异喹啉羧酸的中间体及其制备方法和应用 |
Family Cites Families (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| JPS5759843A (en) * | 1980-09-30 | 1982-04-10 | Neos Co Ltd | Perfluoroalkyl ether amide derivative and its preparation |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4668506A (en) | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
| US4713244A (en) | 1985-08-16 | 1987-12-15 | Bausch & Lomb Incorporated | Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent |
| US4931279A (en) | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| GB2209937B (en) | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| EP0314863B1 (en) | 1987-11-02 | 1994-12-07 | Baylor College Of Medicine | Use of ICAM-1 or its functional derivatives for the treatment of non-specific inflammation |
| EP0326151B1 (en) | 1988-01-29 | 1993-06-16 | Sumitomo Pharmaceuticals Company, Limited | Improved controlled release formulation |
| DE3802996A1 (de) | 1988-02-02 | 1989-08-10 | Cassella Ag | Verwendung von 2-oxo-pyrrolidin-1-acetamid zur bestimmung der glomerulaeren filtrationsrate beim menschen |
| US5424399A (en) | 1988-06-28 | 1995-06-13 | The Children's Medical Center Corporation | Human CR3α/β heterodimers |
| ATE123810T1 (de) | 1988-08-23 | 1995-06-15 | Dana Farber Cancer Inst Inc | Alpha-subeinheit des lfa-1-leukocyt-adhäsions- rezeptors. |
| ES2141076T3 (es) | 1988-09-01 | 2000-03-16 | Bayer Ag | Proteina del receptor de rinovirus humano que inhibe la infectividad del virus. |
| AU4412889A (en) | 1988-09-28 | 1990-04-18 | Dana-Farber Cancer Institute | Intercellular adhesion molecules, and their binding ligands |
| US5149780A (en) | 1988-10-03 | 1992-09-22 | The Scripps Research Institute | Peptides and antibodies that inhibit integrin-ligand binding |
| CA2050329A1 (en) | 1989-03-09 | 1990-09-10 | Timothy A. Springer | Method of treating viral infections using lfa-1 |
| WO1990013316A1 (en) | 1989-04-28 | 1990-11-15 | Baylor College Of Medicine | Dissemination of hiv-1 infected cells |
| CH679207A5 (pt) | 1989-07-28 | 1992-01-15 | Debiopharm Sa | |
| WO1991019511A1 (en) | 1990-06-18 | 1991-12-26 | The General Hospital Corporation | CONTROLLING CELLULAR IMMUNE/INFLAMMATORY RESPONSES WITH β2 INTEGRINS |
| CA2046830C (en) | 1990-07-19 | 1999-12-14 | Patrick P. Deluca | Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer |
| US5318965A (en) | 1990-08-24 | 1994-06-07 | Abbott Laboratories | Quinobenzoxazine, antineoplastic agents |
| EP0546077A1 (en) | 1990-08-27 | 1993-06-16 | Chiron Corporation | Cd18 peptide medicaments for the treatment of disease |
| JP2995860B2 (ja) | 1990-11-27 | 1999-12-27 | 味の素株式会社 | 新規ペプチド |
| US5288854A (en) | 1990-11-28 | 1994-02-22 | Center For Blood Research, Inc. | Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1 |
| CH683149A5 (fr) | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
| CA2120506C (en) | 1991-10-04 | 2000-12-12 | Scott M. Whitcup | Treatment of ocular inflammation by blockage of cell adhesion molecules |
| GB9211268D0 (en) | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
| US5298492A (en) | 1992-08-04 | 1994-03-29 | Schering Corporation | Diamino acid derivatives as antihypertensives |
| MX9305070A (es) | 1992-08-21 | 1994-04-29 | Genentech Inc | Compocicion farmaceutica que contiene un antagonista de lfa-1 para el tratamiento de transtornos o desordenes mediados por el lfa-1 |
| WO1994011400A1 (en) | 1992-11-18 | 1994-05-26 | Helsinki University Licensing Ltd. Oy | Peptides from human icam-2 and from human icam-1 and their analogs for use in therapy and diagnosis |
| HU220137B (hu) | 1993-01-06 | 2001-11-28 | Kinerton Ltd. | Biológiailag lebontható poliészterek és biológiailag aktív polipeptidek ionos molekuláris konjugátumai, eljárás ezek előállítására és eljárás mikrorészecskék előállítására |
| US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| US5424289A (en) | 1993-07-30 | 1995-06-13 | Alza Corporation | Solid formulations of therapeutic proteins for gastrointestinal delivery |
| US5397791A (en) | 1993-08-09 | 1995-03-14 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| EP0656348B1 (de) | 1993-12-03 | 2000-05-03 | F. Hoffmann-La Roche Ag | Essigsäurederivate als Arzneimittel |
| US5470953A (en) | 1993-12-23 | 1995-11-28 | Icos Corporation | Human β2 integrin α subunit |
| EP0762886A4 (en) | 1994-04-19 | 1999-03-31 | Univ Kansas | ICAM-1 / LFA-1 SHORT CHAIN PEPTIDES AND METHODS FOR USE THEREOF |
| US5849327A (en) | 1994-07-29 | 1998-12-15 | Advanced Polymer Systems, Inc. | Delivery of drugs to the lower gastrointestinal tract |
| US5510495A (en) * | 1994-09-19 | 1996-04-23 | The Du Pont Merck Pharmaceutical Company | Process for the isolation and purification of ester functionalized imidazole intermediates by selective hydrolysis |
| US5585359A (en) | 1994-09-29 | 1996-12-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| ATE170179T1 (de) | 1994-11-02 | 1998-09-15 | Merck Patent Gmbh | Adhäsionsrezeptor-antagonisten |
| US5612052A (en) | 1995-04-13 | 1997-03-18 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
| US5747035A (en) | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
| US5877224A (en) | 1995-07-28 | 1999-03-02 | Rutgers, The State University Of New Jersey | Polymeric drug formulations |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US5840332A (en) | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
| CA2250981C (en) | 1996-04-23 | 2002-07-02 | Kinerton Limited | Acidic polylactic polymers |
| HRP970493A2 (en) | 1996-09-23 | 1998-08-31 | Wienman E. Phlips | Oral delayed immediate release medical formulation and method for preparing the same |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| WO1998023608A1 (en) | 1996-11-27 | 1998-06-04 | Dupont Pharmaceuticals Company | Novel integrin receptor antagonists |
| US5968895A (en) | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| US5893985A (en) | 1997-03-14 | 1999-04-13 | The Lincoln Electric Company | Plasma arc torch |
| AR012443A1 (es) | 1997-04-16 | 2000-10-18 | Uriach & Cia Sa J | Nuevas carboxamidas como inhibidores de la agregacion plaquetaria, procedimiento para su preparacion, composiciones farmaceuticas que loscontienen y uso de los mismos en la manufactura de medicamentos |
| UA74531C2 (en) | 1998-03-27 | 2006-01-16 | Genentech Inc | Antagonsists for treating disorders mediated by cd11/cd18 adhesion receptors |
| US6331640B1 (en) | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
| ID29085A (id) | 1998-11-27 | 2001-07-26 | Kanji Takada | Suatu formulasi oral untuk penghantaran obat gastrointestinal |
| IT1304152B1 (it) | 1998-12-10 | 2001-03-08 | Mediolanum Farmaceutici Srl | Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato |
| US6670321B1 (en) | 1998-12-30 | 2003-12-30 | The Children's Medical Center Corporation | Prevention and treatment for retinal ischemia and edema |
| WO2000040262A1 (en) | 1999-01-05 | 2000-07-13 | The Flinders University Of South Australia | Novel agents and methods for treatment and diagnosis of ocular disorders |
| AU2847200A (en) | 1999-01-27 | 2000-08-18 | G.D. Searle & Co. | Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors |
| EP1028114A1 (en) | 1999-02-13 | 2000-08-16 | Aventis Pharma Deutschland GmbH | Novel guanidine derivatives as inhibitors of cell adhesion |
| EP1169024B1 (en) | 1999-03-31 | 2005-12-21 | Janssen Pharmaceutica N.V. | Pregelatinized starch in a controlled release formulation |
| WO2001001964A2 (en) | 1999-06-23 | 2001-01-11 | Sedum Laboratories, Inc. | Ionically formulated biomolecule microcarriers |
| PL354120A1 (en) | 1999-08-18 | 2003-12-29 | Societe De Conseils De Recherches Et D'applicationsociete De Conseils De Recherches Et D'applications Scientifiques S.A.S.S Scientifiques S.A.S. | Sustained release formulation of a peptide |
| ECSP003707A (es) | 1999-10-13 | 2002-05-23 | Novartis Ag | Diazepanes |
| US6605597B1 (en) | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
| US6294522B1 (en) | 1999-12-03 | 2001-09-25 | Cv Therapeutics, Inc. | N6 heterocyclic 8-modified adenosine derivatives |
| AU768324B2 (en) | 1999-12-14 | 2003-12-11 | Genentech Inc. | TNF-alpha antagonist and LFA-1 antagonist for treating LFA-1 or TNF-alpha mediated disorder |
| US7521061B2 (en) | 1999-12-31 | 2009-04-21 | Rutgers, The State University Of New Jersey | Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix |
| US7326425B2 (en) | 1999-12-31 | 2008-02-05 | Rutgers, The State University | Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release |
| WO2001049249A2 (en) | 1999-12-31 | 2001-07-12 | Rutgers, The State University | Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix |
| US20030064105A1 (en) | 2000-08-25 | 2003-04-03 | Myung-Jin Kim | Lipophilic-coated microparticle containing a protein drug and formulation comprising same |
| US6515124B2 (en) | 2000-02-09 | 2003-02-04 | Hoffman-La Roche Inc. | Dehydroamino acids |
| WO2001085677A1 (fr) | 2000-05-05 | 2001-11-15 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derives d'aminoacides et leur application a titre de medicaments |
| GB0011817D0 (en) | 2000-05-16 | 2000-07-05 | Pharmacia & Upjohn Spa | Antagonists of integrin receptors |
| WO2002002539A1 (en) | 2000-06-29 | 2002-01-10 | Abbott Laboratories | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| JP2002030052A (ja) * | 2000-07-18 | 2002-01-29 | Tosoh Corp | ヒドロキシアミノカルボン酸、その用途、及びその製造法 |
| AU2001290272A1 (en) * | 2000-09-27 | 2002-04-08 | Asahi Glass Company, Limited | Process for producing acyl fluoride and carboxylic acid salt |
| AR030817A1 (es) | 2000-10-02 | 2003-09-03 | Novartis Ag | Derivados de diazacicloalcanodiona |
| GB0025208D0 (en) | 2000-10-13 | 2000-11-29 | Euro Celtique Sa | Delayed release pharmaceutical formulations |
| US6653478B2 (en) | 2000-10-27 | 2003-11-25 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators |
| DE10055857A1 (de) | 2000-11-10 | 2002-08-22 | Creative Peptides Sweden Ab Dj | Neue pharmazeutische Depotformulierung |
| GB0028367D0 (en) | 2000-11-21 | 2001-01-03 | Celltech Chiroscience Ltd | Chemical compounds |
| CZ20031380A3 (cs) | 2000-11-28 | 2003-10-15 | Genentech, Inc. | LFA-1 Antagonistické sloučeniny |
| US20030008848A1 (en) | 2000-12-19 | 2003-01-09 | Fleck Roman Wolfgang | Small molecules useful in the treatment of inflammatory disease |
| CA2435415A1 (en) | 2001-01-26 | 2002-08-01 | Debio Recherche Pharmaceutique S.A. | Microparticles of biodegradable polymer encapsulating a biologically active substance |
| EP1231212B1 (en) | 2001-02-06 | 2006-12-20 | Pfizer Products Inc. | Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders |
| AU2002322478A1 (en) | 2001-03-02 | 2002-12-16 | Medimmune, Inc. | Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders |
| JP2005511477A (ja) | 2001-03-19 | 2005-04-28 | プラエシス ファーマシューティカルズ インコーポレーテッド | 持続放出のための医薬調合物 |
| US6872382B1 (en) | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
| DK1392306T3 (da) | 2001-06-06 | 2008-05-19 | Aventis Pharma Ltd | Substituerede tetrahydroisoquinoliner til anvendelse i behandlingen af inflammatoriske sygdomme |
| AU2002359793B2 (en) | 2001-12-19 | 2007-06-14 | Alza Corporation | Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
| JP2005525374A (ja) | 2002-03-04 | 2005-08-25 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | 担体ペプチドを含有する持続放出ドラッグ製剤 |
| MXPA05003063A (es) | 2002-09-20 | 2005-05-27 | Alcon Inc | Uso de inhibidores de la sintesis de citosina para el tratamiento de trastornos de ojos secos. |
| US7785578B2 (en) | 2002-10-11 | 2010-08-31 | Aciont, Inc. | Non-invasive ocular drug delivery |
| RU2005117343A (ru) * | 2002-12-20 | 2006-01-27 | Астразенека Аб (Se) | Новые производные пиперидина в качестве модуляторов хемокинового рецептора ccr5 |
| JP2007501844A (ja) | 2003-08-08 | 2007-02-01 | トランス テック ファーマ，インコーポレイテッド | アリール及びヘテロアリール化合物、組成物並びに使用方法 |
| US7459472B2 (en) | 2003-08-08 | 2008-12-02 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| WO2005042710A1 (en) | 2003-10-28 | 2005-05-12 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of statin to kill ebv-transformed b cells |
| CA2544678C (en) | 2003-11-05 | 2013-12-31 | Sunesis Pharmaceuticals, Inc. | Modulators of cellular adhesion |
| GT200500139A (es) | 2004-06-08 | 2005-07-25 | Metodo para la preparacion de acidos hidroxamicos | |
| CN101166736B (zh) * | 2005-04-28 | 2013-02-06 | 惠氏公司 | 他那普戈特的多晶型ⅱ |
| DK1881823T3 (en) | 2005-05-17 | 2015-03-02 | Sarcode Bioscience Inc | COMPOSITION AND PROCEDURES FOR TREATMENT OF EYE DISORDERS |
| WO2007057919A2 (en) * | 2005-10-25 | 2007-05-24 | Alembic Limited | An improved process for preparation of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine |
| JP4193895B2 (ja) | 2006-10-12 | 2008-12-10 | 横河電機株式会社 | 欠陥検査装置 |
| MX2010004281A (es) | 2007-10-19 | 2010-09-10 | Sarcode Corp | Composiciones y metodos para el tratamiento de la retinopatia diabetica. |
| US8481730B2 (en) * | 2008-01-01 | 2013-07-09 | Cipla Limited | Method of synthesis of Bosentan, its polymorphic forms and its salts |
| WO2009139817A2 (en) | 2008-04-15 | 2009-11-19 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
| US8378105B2 (en) * | 2009-10-21 | 2013-02-19 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
| JP6607780B2 (ja) * | 2012-07-25 | 2019-11-20 | サルコード・バイオサイエンス・インコーポレイテッド | Ｌｆａ−１阻害剤およびその多形 |
-
2013
- 2013-07-25 JP JP2015524447A patent/JP6607780B2/ja active Active
- 2013-07-25 WO PCT/US2013/052044 patent/WO2014018748A1/en active Application Filing
- 2013-07-25 BR BR112015001608-1A patent/BR112015001608B1/pt active IP Right Grant
- 2013-07-25 CN CN201380048592.8A patent/CN104797574B/zh active Active
- 2013-07-25 CN CN201911035155.8A patent/CN110922393A/zh active Pending
- 2013-07-25 CA CA2879982A patent/CA2879982C/en active Active
- 2013-07-25 US US13/950,807 patent/US9085553B2/en active Active
- 2013-07-25 IN IN847DEN2015 patent/IN2015DN00847A/en unknown
- 2013-07-25 KR KR1020157004283A patent/KR102157608B1/ko active IP Right Grant
- 2013-07-25 AU AU2013295706A patent/AU2013295706A1/en not_active Abandoned
- 2013-07-25 MX MX2015001098A patent/MX2015001098A/es active IP Right Grant
- 2013-07-25 EP EP13823367.1A patent/EP2877465A4/en not_active Withdrawn
- 2013-07-25 RU RU2015102926A patent/RU2658015C2/ru active
- 2013-07-25 KR KR1020207026445A patent/KR20200108932A/ko not_active Application Discontinuation
- 2013-07-25 EP EP20153723.0A patent/EP3715345B8/en active Active
-
2015
- 2015-01-23 MX MX2020001602A patent/MX2020001602A/es unknown
- 2015-06-23 US US14/747,745 patent/US9708303B2/en active Active
- 2015-11-03 HK HK15110817.3A patent/HK1210145A1/xx unknown
- 2015-11-26 HK HK15111648.6A patent/HK1210782A1/xx unknown
-
2017
- 2017-06-13 US US15/621,141 patent/US10214517B2/en active Active
- 2017-11-22 AU AU2017265071A patent/AU2017265071B2/en active Active
-
2018
- 2018-07-19 JP JP2018135758A patent/JP2018162313A/ja active Pending
-
2019
- 2019-01-15 US US16/247,843 patent/US10906892B2/en active Active
- 2019-07-30 AU AU2019210525A patent/AU2019210525B2/en active Active
-
2020
- 2020-06-03 JP JP2020096854A patent/JP7008750B2/ja active Active
- 2020-12-02 AU AU2020281063A patent/AU2020281063A1/en not_active Abandoned
-
2023
- 2023-07-04 AU AU2023204287A patent/AU2023204287A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN00847A (pt) | ||
| HRP20190491T1 (hr) | Spojevi 1-arilkarbonil-4-oksi-piperidina korisni za liječenje neurodegenerativnih bolesti | |
| HUE041553T2 (hu) | Lizoszomális tárolási betegségek (LSD) kezelése és génterápia | |
| HK1198297A1 (en) | Compositions, uses and methods for treatment of metabolic disorders and diseases | |
| EP2938616A4 (en) | PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES | |
| HUE037600T2 (hu) | Vegyületek és készítmények paraziták által okozott fertõzések kezelésére | |
| EP2773342A4 (en) | COMPOSITIONS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | |
| PH12015500376A1 (en) | Novel bicyclic pyridinones | |
| WO2012104823A3 (en) | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases | |
| PL2892556T3 (pl) | Kompozycje i sposoby odnoszące się do leczenia chorób | |
| IL238592B (en) | Compounds for the treatment of liver diseases | |
| EP2709632A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES | |
| HK1208454A1 (zh) | 治療細菌性疾病的嘧啶衍生物 | |
| IL234796B (en) | Compounds for the treatment of diseases related to ischemia-reperfusion | |
| PL395469A1 (pl) | Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego | |
| HK1157189A1 (en) | Pharmaceutical composition for the treatment of tumor diseases | |
| GB201217331D0 (en) | Novel compound useful for the treatment of infectious diseases | |
| AU2011900644A0 (en) | Therapeutic Uses of SLIRP | |
| AU2011903764A0 (en) | Treatment of bone diseases |